

Assessing the Quality of Randomized Controlled Trials of Complex Regional Pain Syndrome Published in the Journal of Clinical Pain Medicine Field

Seung Wook Lee

Hanyang University Medical School: Hanyang University College of Medicine

Kyu Shik Kim

Hanyang University Medical School: Hanyang University College of Medicine <https://orcid.org/0000-0001-8755-0774>

Jae Hoon Chung

Sungkyunkwan University School of Medicine

Hyung Joon Park

Hanyang University Medical School: Hanyang University College of Medicine

Yong Seok Sohn

Hanyang University Medical School: Hanyang University College of Medicine

Woo Jae Jeon

Hanyang University Medical School: Hanyang University College of Medicine

Sang Yun Cho

Hanyang University Medical School: Hanyang University College of Medicine

Woo Jong Shin (✉ swj0208@hanyang.ac.kr)

Hanyang University Medical School: Hanyang University College of Medicine <https://orcid.org/0000-0002-3786-2267>

Research article

Keywords: Reporting Quality, Randomized Control Trial, CONSORT Statement, Complex regional pain syndrome

Posted Date: September 14th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-69974/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Complex regional pain syndrome is a disease characterized by chronic pain caused by tissue damage and worsens over time. The quality of randomized controlled trials on complex regional pain syndrome is low due to the rarity of the disease and difficulty in designing studies. Therefore, we evaluated the completeness of evidence by assessing the quality.

Methods: We searched articles that were published between 1998 and 2017. The quality was assessed using the Jadad scale, van Tulder scale, and the Cochrane collaboration risk of bias tool.

Results: A total of 72 articles on complex regional pain syndrome have been published. Only 31 articles were found to have a low risk of bias according to the Cochrane Collaboration. On the Jadad and van Tulder scale, 52 and 58 articles, respectively, were assessed as high quality. Only a few trials described the randomization method adequately and presented allocation concealment correctly. We also found that research trials with funding statements had higher Jadad scales than unfunded ($P = 0.03$). Furthermore, articles that described the sample size were of significantly higher quality ($P < 0.01$) than those that did not.

Conclusions: There was no observed improvement in quality over time. In particular, the performance rate of the allocation concealment for the analyzed papers was low. In addition, we found that the number of high-quality articles increased when institutional review board approval was granted and funding provided. For the future, we recommend that researchers focus their efforts on conducting high-quality studies.

Background

Evidence-based Medicine (EBM) refers to the rational approach to individual patient care with an emphasis on integrating data from clinical studies on diagnosis, treatment, and disease prevention (1, 2). Increasingly, EBM is based on the randomized controlled trial (RCT) approach (3). The typical design of RCTs minimizes the risk of bias, optimizes the level of evidence, and ensures the generation of highly reliable results (4). However, RCT design does not eliminate bias completely. Bias that arises at the RCT design, performance, reporting, or application phases may lead to an underestimation or overestimation of the true intervention effect (5). Since RCT results are applied in clinical practice, RCTs should involve high standards in order to minimize bias (6).

An objective methodological quality evaluation of RCTs is certainly a necessary review process to enable scientific medical treatment (7). At the time of writing, the International Committee of Medical Journal Editors recommends the Consolidated Standards of Reporting Trials (CONSORT) statement as a guideline for RCT quality improvement (8). The CONSORT guidelines assist physicians in the understanding, performance, and analysis of RCTs (9). However, the CONSORT statement is not intended as a tool for the evaluation of RCT quality.

The quality assessment for an RCT report involves evaluation of whether the study design, procedures, and statistical analyses justify the authors' conclusions (10). This process therefore identifies erroneous data and unsubstantiated conclusions that require exclusion from clinical application, and thereby reduces the potential for non-justified medical costs (11). Methods to evaluate RCT quality include checklists, scales, and the assessment of individual indices. To evaluate bias, a Jadad quality assessment scale (12) is widely used in the evaluation of RCT quality. However, a further requirement in RCTs is the avoidance of selection bias via appropriate treatment allocation and allocation concealment (13), which are factors that are not typically addressed by the Jadad scale. Tools comprising items for allocation concealment include the van Tulder scale (VTS) (14) and the Cochrane Collaboration Risk of Bias Tool (CCRB) (15).

Complex regional pain syndrome (CRPS) is associated with various disorders, such as localized skin color and temperature changes, edema, and severe pain, but it is not yet fully understood (16, 17). Even after the development of new diagnostic criteria, disagreements about CRPS diagnoses and treatments continue (17). Physicians and patients have a low understanding of CRPS, and thus, the time period before patients are treated by pain specialists is usually long (18). Although several RCTs have been reported on CRPS, the quality of articles is typically lower than it could be due to the rarity of the disease itself and difficulty in designing studies (19, 20). Therefore, we evaluated the completeness of the presented evidence by assessing the quality of RCTs on CRPS.

Although the evaluation of RCT quality has been the subject of several recent studies (3, 7, 11, 21, 22) to date, no study has performed a systematic evaluation of the quality of RCTs on CRPS.

Methods

1. Subjects

To identify all RCT articles on CRPS between 1998 and 2017, two independent authors (Park and Ryu) performed a manual search of PubMed, EMBASE, and Cochrane library. Then, a third researcher (Shin) adjusted the two sets of data in order to select articles for inclusion in the present study.

2. Assessment of RCT quality

RCT quality was assessed using the Jadad scale, the VTS, and the CCRBT by the two independent researchers.

Jadad Scale

The Jadad scale score comprises a total of five points: two points for randomization, two points for blinding, and one point for dropout. If the total score is > 3 points, the RCT is considered high quality. If the total score is < 2 points, the RCT is considered low quality. For RCTs which had a precluded double-blind design, they are considered high quality when the total score is > 2 (12).

van Tulder Scale

The VTS assesses the following 11 aspects of RCT quality: randomization, allocation concealment, baseline characteristics, patient blinding, care provider blinding, observer blinding, co-intervention, compliance, drop-out rate, end-point assessment time point, and intention-to-treat analysis (14). For each item, the response 'yes', 'no', or 'do not know' is applied. If the criteria for five or more items are met (> 5 points), the RCT is evaluated as high quality (14).

Cochrane Collaboration risk of bias tool

The CCRBT assesses the following six domains of RCT quality: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential threats to validity (15). Each domain is assessed using a 'yes', 'no', or 'unclear' response, which indicate a low risk of bias, a high risk of bias, and an uncertain risk of bias, respectively. If the response in the first three domains is 'yes', and no important concerns are identified in relation to the last three domains, the RCT is classified as having a low risk of bias. If the response in ≤ 2 domains is 'unclear' or 'no', the study is classified as having a moderate risk of bias. If the response in ≥ 3 domains is 'unclear' or 'no', the RCT is classified as having a high risk of bias (23).

3. Evaluation of RCT quality according to other factors

Changes in frequency over time of statements concerning sample size, conflict of interest, funding sources, institutional review board (IRB) approval, double blinding, and allocation concealment were determined.

4. Statistical analysis

Analysis of RCT quality was conducted at 5-year intervals from 1998. For each assessment tool, the score and time flow were compared using a one-way ANOVA. Chi-square tests were used to analyze the association between high quality article status according to the Jadad score and according to the CCRBT. Fisher's exact tests were used to analyze the associations between high quality article status according to the Jadad score, VTS, and CCRBT findings. A Student's *t*-test was used to analyze IRB approval, blinding, funding, conflict of interest, allocation, sample size, and country distribution. SPSS version 24.0 (SPSS Inc., Chicago, Illinois, USA) was used for statistical analysis and a *P*-value < 0.05 was considered to be statistically significant.

Results

1. Analysis of topics related to the articles

This is the first study to assess the quality of RCTs on CRPS in the field of pain medicine. There was no distinct intervention therapy in the management of CRPS during the period of 1998-2007, but from 2008-2017 pain physicians tried several treatments, such as rehabilitation therapy, drugs, and regional blocks,

to reduce the complications of CRPS syndrome (Table 1). With respect to drug therapy, N-Methyl-D-aspartate (NMDA) blockers were most commonly investigated (Table 1).

2. Characteristics of RCTs according to publication year.

In total, 72 original RCT articles on CRPS were published between 1998 and 2017 (Figure 1). The number of RCTs reported in the 1998-2002, 2003-2007, 2008-2012, and 2013-2017 time periods were 8, 14, 25, 25, respectively (Table 2). The complete reports, including sample sizes and conflicts of interest, were described in 37 (51.4%) and 6 (8.3%) of the RCTs, respectively (Table 2). The funding source was described in 53 (73.6%) papers. This reporting arose significantly over time (from 75.0% in the early period to 80.0% in the late period ($P = 0.05$, Table 2)). On average, 84.7% of the RCTs reported that they received IRB approval, and the frequency of IRB reporting did not rise over time. In addition, blinding was performed in 55 (76.4%) of the RCT reports (from 1998 to 2017). The reporting of blinding did not rise significantly as the study period progressed from early to late periods (from 75.0% to 72.0%; $P = 0.94$). Thirty-nine (54.2%) of the total reports described the allocation concealment ($P = 0.82$, Table 2).

3. Qualitative change in RCTs over time

1) Jadad scale:

RCT quality did not increase from the first RCT publication in 1998 to all other publications up to 2017. Assessment of RCT quality at 5-year intervals starting from 1998 showed that the mean Jadad scale score from 1998 to 2002 was 3.50 ± 0.76 . Then, from 2013 to 2017, the mean Jadad score was 2.92 ± 1.41 . The overall mean Jadad score was 3.25 ± 1.45 ($P = 0.52$, Table 3). Eight high-quality articles (100%) were published between 1998 and 2002, and 16 (64.0%) high quality articles were published between 2013 and 2017 ($P = 0.27$, Table 3).

2) van Tulder scale:

From 1998 to 2002, the mean VTS score was 6.50 ± 1.20 . From 2013 to 2017, the mean VTS score was 6.20 ± 2.10 ($P = 0.92$, Table 3). The overall mean score was 6.35 ± 2.04 ($P = 0.92$, Table 3). The number of high quality RCTs published from 1998 to 2002 was 8 (100%)., Then, from 2013 to 2017, there were 18 (72.0%) high quality RCTs out of the 25 total RCTs published in that time period ($P = 0.38$, Table 3).

3) Cochrane collaboration risk of bias tool:

According to the CCRBT analysis, only one (12.5%) low risk of bias RCT was published between 1998 and 2002. From 1998 to 2007 and 2013 to 2017, zero (0%) and four (16.0%) RCTs on CRPS, respectively, were published that had a moderate risk of bias ($P = 0.24$, Table 3).

4) Association between RCT quality and other factors

The RCT papers were divided according to whether the funding source, IRB approval, conflict of interest, and sample size were described or not. The papers that described the funding source had significantly

higher quality, as determined using the Jadad scales ($P = 0.03$, Table 4). The papers that described sample size were of significantly higher quality, as determined by the Jadad and van Tulder scales ($P < 0.01$), respectively, and were significantly more likely to be low risk of bias reports, as determined by the CCRBT ($P < 0.01$, Table 4).

5) Analysis of RCT quality according to country

The 72 RCT articles published between 1998 and 2017 concerned the following countries: Europe (N = 41), North America (N = 13), Middle East (N = 8), Oceania (N = 5), Asia (N = 3), and South America (N = 2). There was no difference in the quality evaluation according to the countries ($P = 0.11$, Table 5).

Discussion

CRPS is a neuropathic pain disorder that occurs after tissue injuries and is known to cause tissue deterioration over time. Patients may present various symptoms, including severe pain, but the disease has been difficult to identify. Management of complications and symptoms has been so diverse that many different attempts have been made, but there has never been a standard treatment. Although the mechanism of the disease is not clear, it has been mainly treated with a variety of drugs, but recently, various methods, such as rehabilitation and nerve block, have also been tried.

The present analysis of all 72 RCTs on CRPS revealed a quantitative and qualitative improvement over time. However, the degree of improvement was suboptimal, and the identified deficiencies should be addressed in future studies.

Several previous investigations have focused on the issue of RCT quality (12, 21, 22, 24, 25). They found that the number of RCTs published in journals from the 1980s to the 2000s increased over time. They also found an improvement in RCT quality over time (24). However, the authors applied the Jadad scale only and no statistical analyses of the data were done. To address these issues, previous studies showed a quantitative increase in RCTs over time (21, 22). In the present study, we saw a recent increase in the number of RCTs published from the analysis of outcomes at 5-year intervals.

To evaluate adherence to the CONSORT statement, Uetani *et al.*(4) identified 98 RCTs and reported that only 11 of these 98 RCTs adhered to each item of the CONSORT statement. However, since the CONSORT statement is not a quality assessment tool, no statistical analysis of each article's quality was possible. There are many tools for quantitatively assessing the quality of RCTs such as Moher (25), Chalmers (26), Jadad (12), van Tulder (14), Cochrane (15) and others. In this study, we used three tools, which were the Jadad scale, van Tulder scale, and CCRBT, which can comprehensively analyze the various elements of the CONSORT statement.

In an analysis of the methodological quality of RCTs published in *Rheumatology International* from 1981 to 2012, Lee *et al.*(21) confirmed that there was a quantitative increase in quality. However, the authors reported that the increase in quality was suboptimal. To fulfill the criteria for a high quality RCT, Lee *et al.*

(21) proposed that authors should improve the reporting of allocation concealment, generation of randomization sequences, design of double blinded studies, and IRB approval. In the present study, double-blinded studies accounted for 76.4% of all RCTs published between 1998 and 2017 (Table 2). As in previous studies, inadequate explanations of blinding and the absence of any references to allocation concealment were factors that caused the evaluation of an RCT to be poor quality. Hewitt *et al.*(27) reported that 46% of the RCTs published in 2000 in the world's four major medical journals (*The British Medical Journal*, *The Journal of the American Medical Association*, *The Lancet*, and *The New England Journal of Medicine*) had involved inappropriate or uncertain concealment of allocation. Moreover, Schulz *et al.*(23) suggested that without concealment of allocation, randomization could be compromised and distorted by more than 40% in the process of performing even if the randomization procedure is appropriate. Based on the present study, appropriate blinding and allocation concealment are associated with RCT quality, therefore, if the quality of these items are improved, the RCT quality will also be improved.

As shown in previous studies, articles published after IRB review had a relatively high quality (22). IRB approval is a valuable step in terms of ensuring valid study design and performance, and the benefit of establishing a study plan for the IRB approval process is likely to be shown in the observed increase in the publishing rate of high quality articles.

Clifford *et al.*(28) hypothesized that RCTs supported by funding would be of higher quality than those without funding, as they would be large-scale and well-designed. However, they found no association between funding source and article quality in an analysis of 100 RCTs published in a total of five high impact, peer-reviewed general medical journals. We investigated articles related to CRPS published over the past 20 years in the pain medicine field. Contrastingly, funding sources significantly impacted RCT quality, which was evaluated with the Jadad scale in the present study ($P = 0.03$, Table 4). In the case of research that received financial support, it is judged that there are many high-quality articles because it is possible to do well-designed research design and large-scale research.

Recently, many editors have requested clarification on the number of sample size of the research subjects. In this study, about 37 articles (51.4%) based on the Jadad method provided the basis for the sample size of the study subjects, of which 34 studies (91.9%) showed significantly higher quality than those which did not provide sample size calculation ($P < 0.01$, Table 2). The value of the van Tulder scale was 7.59 ± 1.44 , and 36 studies (97.3%) showed a high quality evaluation, showing a significant difference ($P < 0.01$, Table 2).

In recent years, there has been a debate about whether the conflict of interest should be viewed as a new bias evaluation area or not (29). However, it is necessary to examine factors that have not been agreed to yet, and that may have an effect on bias.

Future RCTs should address the complexity of CRPS, which has the characteristics of spontaneous pain, allodynia, hyperalgesia of the limbs, and abnormal findings in the autonomic and motor nervous systems. CRPS potentially affects almost all systemic organs. Risk factors include smoking, genetic

factors, psychological factors, and other factors that have not been yet been detailed. In 1994, the International Association for the Study of Pain (IASP) established diagnostic criteria for CRPSs. However, even after the development of the diagnostic criteria, disagreements persisted. There are two types of CRPS. Type 1 CRPS is not associated with obvious nerve damage and most patients belong to Type 1. There is no definite cure, and several therapies have been tested.

Although several RCTs have been reported for CRPS, the number and quality of papers may be lessened due to the rarity of the CRPS disease itself and the difficulty in designing the research. No definitive pathophysiology or treatment has been established yet for the disease. Therefore, the quality of the RCTs related to CRPS should be assessed for completeness and the information of each article should be validated.

This study had some limitations. As noted in previous RCT qualitative studies, no consensus has yet been reached concerning the optimal method of quality assessment, and no highly accurate and valid tools for quality assessment have been established (30). To overcome these limitations, the present study applied three different tools: the Jadad scale, the VTS, and the CCRBT.

The extraction and quality evaluation of RCTs may be influenced by the subjective judgement of the researcher. In the present study, thus, two independent researchers were responsible for data extraction and evaluation. Moreover, the data was evaluated and adjusted by a third researcher to optimize objectivity and reliability. To our knowledge, the present study represents the first systematic evaluation of all RCTs on CRPS published to date. The results suggest strategies to improve the quality of research on CRPS.

Conclusion

The present data suggests that qualitative improvements for RCTs on CRPS are necessary. Even though double blind study designs and allocation concealments were performed in many of the selected RCTs, the quality of the RCTs was found to be suboptimal. However, sample size calculations, which recently editorial committees have increasingly requested authors to report, appeared to be a significant factor in improving the quality of RCTs. To achieve a significant improvement, pain practitioners and medical researchers require increased awareness of the criteria of the CONSORT statement, and future RCTs should involve funding sources, adequate randomization, blinding, IRB approval, and maintenance of allocation concealment.

We suggest that sample size calculations should be a possible new component of quality assessment tool in future studies.

Abbreviations

Evidence-based Medicine (EBM), Randomized controlled trial (RCT), Consolidated Standards of Reporting Trials (CONSORT), Van Tulder scale (VTS), Cochrane Collaboration Risk of Bias Tool (CCRBT), Complex

regional pain syndrome (CRPS), institutional review board (IRB), N-Methyl-D-aspartate (NMDA), International Association for the Study of Pain (IASP)

Declarations

Ethics Approval and Consent to Participate : Not applicable

Consent for Publication : Not applicable

Availability of Data and Materials: The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Competing Interest: None of the authors have a conflict of interest as to this work.

Funding: This project was supported by a grant from the Hanyang University. Dr. Woo Jong Shin have received funding from Hanyang University Research Institute (201700000003013) in the design of the study and collection.

Authors' contributions : all authors have read and approved the manuscript

Conceptualization: Kyu Shik Kim, Jae Hoon Chung, Hyung Joon Park.

Data curation: JHC, HJP, YSS, WJJ.

Formal analysis: KSK, SWL.

Funding acquisition: WJS.

Investigation: WJS, SWL

Methodology: KSK, JHC.

Project administration: HJP.

Resources: HJP, YSS.

Software: YSS, WJJ, SYC.

Supervision: WJS, SWL.

Validation: SYC.

Visualization: YSS, WJJ.

Writing – original draft: SWL.

Writing – review & editing: WJS, SWL.

Acknowledgements :

The authors gratefully acknowledge the support of librarian of the Hanyang University Guri Hospital, Hyun Jung Yi.

Our article for the PRISMA checklist is not applicable because we analyzed previous articles with using three different tools to figure out the qualities of RCTs related with Complex regional pain syndrome.

References

1. Hess DR. What is evidence-based medicine and why should I care? *Respiratory care* 2004;**49**(7): 730-41.
2. Smith R, Rennie D. Evidence-based medicine—an oral history. *Jama* 2014;**311**(4): 365-7.
3. Chung JH, Kang DH, Jo JK, Lee SW. Assessing the quality of randomized controlled trials published in the Journal of Korean Medical Science from 1986 to 2011. *Journal of Korean medical science* 2012;**27**(9): 973-80.
4. Uetani K, Nakayama T, Ikai H, Yonemoto N, Moher D. Quality of reports on randomized controlled trials conducted in Japan: evaluation of adherence to the CONSORT statement. *Internal medicine (Tokyo, Japan)* 2009;**48**(5): 307-13.
5. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *Jama* 1996;**276**(8): 637-9.
6. Altman DG. Better reporting of randomised controlled trials: the CONSORT statement. *BMJ (Clinical research ed)* 1996;**313**(7057): 570-1.
7. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. *Jama* 2002;**287**(21): 2801-4.
8. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *Jama* 2001;**285**(15): 1987-91.
9. Hill J, Bullock I, Alderson P. A summary of the methods that the National Clinical Guideline Centre uses to produce clinical guidelines for the National Institute for Health and Clinical Excellence. *Annals of internal medicine* 2011;**154**(11): 752-7.
10. Autorino R, Borges C, White MA, Altunrende F, Perdona S, Haber GP, De Sio M, Khanna R, Stein RJ, Kaouk JH. Randomized clinical trials presented at the World Congress of Endourology: how is the quality of reporting? *Journal of endourology* 2010;**24**(12): 2067-73.
11. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *Jama* 1995;**273**(5): 408-12.
12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Controlled clinical trials*

- 1996;**17**(1): 1-12.
13. Moher D, Cook DJ, Jadad AR, Tugwell P, Moher M, Jones A, Pham B, Klassen TP. Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. *Health technology assessment (Winchester, England)* 1999;**3**(12): i-iv, 1-98.
 14. van Tulder M, Furlan A, Bombardier C, Bouter L. Updated method guidelines for systematic reviews in the cochrane collaboration back review group. *Spine* 2003;**28**(12): 1290-9.
 15. Higgins J, Altman D. "Chapter 8: Assessing risk of bias in included studies". In: Higgins J, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions* version 5.0. Chichester, UK: Sons, Ltd; 2008.
 16. Harden RN, Bruehl S, Perez RS, Birklein F, Marinus J, Maihofner C, Lubenow T, Buvanendran A, Mackey S, Graciosa J, Mogilevski M, Ramsden C, Chont M, Vattne JJ. Validation of proposed diagnostic criteria (the "Budapest Criteria") for Complex Regional Pain Syndrome. *Pain* 2010;**150**(2): 268-74.
 17. Marinus J, Moseley GL, Birklein F, Baron R, Maihofner C, Kingery WS, van Hilten JJ. Clinical features and pathophysiology of complex regional pain syndrome. *The Lancet Neurology* 2011;**10**(7): 637-48.
 18. Rockett M. Diagnosis, mechanisms and treatment of complex regional pain syndrome. *Current opinion in anaesthesiology* 2014;**27**(5): 494-500.
 19. Terkelsen AJ, Gierthmuhlen J, Finnerup NB, Hojlund AP, Jensen TS. Bilateral hypersensitivity to capsaicin, thermal, and mechanical stimuli in unilateral complex regional pain syndrome. *Anesthesiology* 2014;**120**(5): 1225-36.
 20. Breuer AJ, Mainka T, Hansel N, Maier C, Krumova EK. Short-term treatment with parecoxib for complex regional pain syndrome: a randomized, placebo-controlled double-blind trial. *Pain physician* 2014;**17**(2): 127-37.
 21. Lee JW, Chung JH, Jo JK, Lee SW. Analysis of randomized controlled trials in Rheumatology International from 1981 to 2012: methodological assessment. *Rheumatology international* 2014;**34**(9): 1187-93.
 22. Kim KS, Chung JH, Jo JK, Kim JH, Kim S, Cho JM, Cho HJ, Choi HY, Lee SW. Quality of randomized controlled trials published in the International Urogynecology Journal 2007-2016. 2018;**29**(7): 1011-17.
 23. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. *Lancet* 2002;**359**(9306): 614-8.
 24. Lee JY, Chung JH, Kang DH, Lee JW, Moon HS, Yoo TK, Choi HY, Lee SW. Quality Assessment of Randomized Controlled Trials Published in the Korean Journal of Urology Over the Past 20 Years. *Korean journal of urology* 2011;**52**(9): 642-46.
 25. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. *International journal of technology assessment in health care* 1996;**12**(2): 195-208.

26. Chalmers TC, Smith H, Jr., Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A. A method for assessing the quality of a randomized control trial. *Controlled clinical trials* 1981;**2**(1): 31-49.
27. Hewitt C, Hahn S, Torgerson DJ, Watson J, Bland JM. Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals. *BMJ (Clinical research ed)* 2005;**330**(7499): 1057-8.
28. Clifford TJ, Barrowman NJ, Moher D. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. *BMC health services research* 2002;**2**(1): 18.
29. Ngo-Metzger Q, Moyer V, Grossman D, Ebell M, Woo M, Miller T, Brummer T, Chowdhury J, Kato E, Siu A, Phillips W, Davidson K, Phipps M, Bibbins-Domingo K. Conflicts of Interest in Clinical Guidelines: Update of U.S. Preventive Services Task Force Policies and Procedures. *American journal of preventive medicine* 2018;**54**(1s1): S70-s80.
30. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. *Journal of evaluation in clinical practice* 2012;**18**(1): 12-8.